These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715 [TBL] [Abstract][Full Text] [Related]
23. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. Mulé JJ; Yang J; Shu S; Rosenberg SA J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106 [TBL] [Abstract][Full Text] [Related]
24. Natural and antibody-dependent cytotoxicity in different clinical stages of human immunodeficiency virus type 1 infection. Ljunggren K; Karlson A; Fenyö EM; Jondal M Clin Exp Immunol; 1989 Feb; 75(2):184-9. PubMed ID: 2649286 [TBL] [Abstract][Full Text] [Related]
25. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing. Wiebke EA; Custer MC; Rosenberg SA; Lotze MT J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373 [TBL] [Abstract][Full Text] [Related]
32. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. Hu PF; Hultin LE; Hultin P; Hausner MA; Hirji K; Jewett A; Bonavida B; Detels R; Giorgi JV J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Nov; 10(3):331-40. PubMed ID: 7552495 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of lymphokine-activated killer activity during HIV infection: role of HIV-1 gp41 synthetic peptides. Cauda R; Tumbarello M; Ortona L; Kennedy RC; Shuler KR; Chanh TC; Kanda P Nat Immun Cell Growth Regul; 1990; 9(6):366-75. PubMed ID: 2087245 [TBL] [Abstract][Full Text] [Related]
34. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. Johansson SE; Rollman E; Chung AW; Center RJ; Hejdeman B; Stratov I; Hinkula J; Wahren B; Kärre K; Kent SJ; Berg L Viral Immunol; 2011 Oct; 24(5):359-68. PubMed ID: 21958370 [TBL] [Abstract][Full Text] [Related]
35. Neutralizing antibodies in relation to antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus type I. Böttiger B; Ljunggren K; Karlsson A; Krohn K; Fenyö EM; Jondal M; Biberfeld G Clin Exp Immunol; 1988 Sep; 73(3):339-42. PubMed ID: 3208445 [TBL] [Abstract][Full Text] [Related]
36. NKG2D Acts as a Co-Receptor for Natural Killer Cell-Mediated Anti-HIV-1 Antibody-Dependent Cellular Cytotoxicity. Parsons MS; Richard J; Lee WS; Vanderven H; Grant MD; Finzi A; Kent SJ AIDS Res Hum Retroviruses; 2016; 32(10-11):1089-1096. PubMed ID: 27487965 [TBL] [Abstract][Full Text] [Related]
37. The effect of acute exercise on lymphocyte subsets, natural killer cells, proliferative responses, and cytokines in HIV-seropositive persons. Ullum H; Palmø J; Halkjaer-Kristensen J; Diamant M; Klokker M; Kruuse A; LaPerriere A; Pedersen BK J Acquir Immune Defic Syndr (1988); 1994 Nov; 7(11):1122-33. PubMed ID: 7932079 [TBL] [Abstract][Full Text] [Related]
38. Functional advantage of educated KIR2DL1(+) natural killer cells for anti-HIV-1 antibody-dependent activation. Gooneratne SL; Center RJ; Kent SJ; Parsons MS Clin Exp Immunol; 2016 Apr; 184(1):101-9. PubMed ID: 26647083 [TBL] [Abstract][Full Text] [Related]
39. Clinical progression of HIV infection: role of NK cells. Bruunsgaard H; Pedersen C; Skinhøj P; Pedersen BK Scand J Immunol; 1997 Jul; 46(1):91-5. PubMed ID: 9246213 [TBL] [Abstract][Full Text] [Related]